Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas
Journal
Journal of the Formosan Medical Association
Journal Volume
120
Journal Issue
1
Pages
293-302
Date Issued
2021
Author(s)
Wang Y.-T.
Yeh Y.-C.
Abstract
Background: Primary intestinal lymphomas (PILs) are rare, and this study compared the clinical outcomes of aggressive primary intestinal B-cell lymphomas (aB-PILs) and T/natural killer-cell lymphomas (T/NK-PILs). Methods: The clinical information of patients diagnosed with aggressive PILs at our institution between 1995 and 2015 were retrospectively investigated. Pathological subtypes were confirmed according to the 2016 revision of the World Health Organization classification. The correlation between clinicopathological features and overall survival (OS) was determined using univariate and multivariate analyses. Results: Cases of T/NK-PILs had higher initial bowel perforation incidence (67% vs. 7%, P < 0.001) and lower complete response rate to first-line chemotherapy regimens (22% vs. 69%, P = 0.009) than aB-PILs. Patients with aB-PILs had a better 5-year event-free survival rate (55.8% vs. 13.9%, P = 0.026) and a 5-year OS rate (74.3% vs. 29.6%, P = 0.036) than those with T/NK-cell lymphomas. Multivariate analysis identified that female gender and stage III/IV were unfavorable prognostic factors. Among the 54 patients with diffuse large B-cell lymphoma (DLBCL), those with International Prognostic Index (IPI) scores of 0–2 had a better 5-year OS rate than those with scores of 3–5 (84.2% vs. 46.8%, P = 0.002). IPI scores of 3–5 (P = 0.026) and tumors located in the large intestine (P = 0.015) were poor prognostic factors based on the multivariate analysis. Conclusion: The prognosis of T/NK-PILs was less favorable than that of aB-PILs. Female gender, stage III/IV disease, DLBCL with IPI scores of 3–5, or tumors in the large intestine were poor prognostic factors. ? 2020
SDGs
Other Subjects
cyclophosphamide; doxorubicin; epirubicin; etoposide; fluorodeoxyglucose; ifosfamide; methotrexate; prednisone; rituximab; vincristine; adolescent; adult; aged; Article; B cell lymphoma; Burkitt lymphoma; cancer classification; cancer combination chemotherapy; cancer diagnosis; cancer incidence; cancer prognosis; cancer staging; carcinogenesis; child; clinical feature; clinical outcome; colon fibroscopy; comparative study; diffuse large B cell lymphoma; drug megadose; event free survival; female; fiberscope endoscopy; human; International Prognostic Index; intestine endoscopy; intestine lymphoma; major clinical study; male; mantle cell lymphoma; marginal zone lymphoma; multiple cycle treatment; NK T cell lymphoma; overall survival; peripheral T cell lymphoma; positron emission tomography-computed tomography; primary tumor; retrospective study; treatment outcome; treatment response; tumor localization; tumor volume; whole body CT; diffuse large B cell lymphoma; immunophenotyping; intestine perforation; middle aged; mortality; pathology; peripheral T cell lymphoma; survival rate; treatment outcome; young adult; Adult; Aged; Female; Humans; Immunophenotyping; Intestinal Perforation; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult
Publisher
Elsevier B.V.
Type
journal article